Intelligent Bio Solutions Inc. — Cyborg Score 4/10
Mixed
Point-of-care drug testing and screening
Strategic Profile
The company's system screens for recent drug use including opiates, cocaine, methamphetamine, and cannabis, with sample collection in seconds and results in under ten minutes, positioning it as a valuable tool for employers in safety-critical industries. In June 2026, INBS initiated a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance, marking a critical step toward capturing the large U.S. drug testing market.
Cyborg Score Rationale
INBS has a differentiated technology and international commercial traction with 480+ accounts across 35 territories. However, the company faces headwinds: stock has declined 88% year-over-year, it remains pre-FDA approval for the U.S. market, and revenue metrics are not publicly available. Patent-pending technology and first-mover advantage in fingerprint-sweat drug testing provide upside potential if U.S. regulatory approval materializes.
Top Insights
Commercial traction in 24 countries with over 450 active accounts, targeting U.S. market where over 55 million drug tests are performed annually
Validation study launched to reduce analysis time, with goal of achieving two-minute test results for roadside drug testing applications
Pre-revenue or minimal revenue profile with significant shareholder dilution in past 12 months, creating near-term cash burn risk
Secondary product SmarTest Patch is a wearable device detecting drug use over 7-10 days for justice and rehabilitation settings
Named Competitors
LabCorp Drug Testing Services — Large clinical laboratory and drug testing provider
Quest Diagnostics — Leading clinical laboratory and workplace drug testing provider
SmarTest Patch — Wearable sweat-based drug detection device for continuous monitoring
Recent Developments
(June 2026) Initiated FDA 510(k) Method Comparison Study for U.S. market clearance of Intelligent Fingerprinting Drug Screening System
(May 2026) Announced validation study to reduce analysis time targeting two-minute test goal for roadside drug testing
(March 2026) Received and deployed first shipment of readers under strategic manufacturing partnership with Syrma Johari
Open the full interactive Intelligent Bio Solutions Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.